Healthcare at home is a provider of out-of-hospital healthcare, this can be at home, at work, or in the community. It operates through working with three kinds of provider: public, pharmaceutical companies, and private companies. It employs 1500 staff throughout the UK of which over 800 are healthcare professionals.
Healthcare at Home began as a supplier of pharmaceutical products to patients in their own homes. In 2013 Healthcare at Home took over the business of drug delivery company, Medco Health Solutions when it pulled out of the UK market. The company has evolved to carry out more than just drug delivery.
The company's strategy is to capitalise off the growing market for intermediate/complex care. This strategy is twofold: to further develop existing expertise in providing medication-related home health care services; and to expand provision of large-scale, clinically-lead services to the NHS and private sector. Their strategic report specifically points out how “the pressure on public finances and the drive to move patient care towards the community setting are both continuing”, which puts them in a secure position.
They work with 48 pharmaceutical companies to provide their products to the 98,000 patients they support. With private providers they act as a subcontractor to directly provide clinical services to patients including: physiotherapy, occupational health, chemotherapy, IV antibiotics, enteral feeding, and palliative care.
According to accounts at Companies House, Healthcare at Home reported revenue for the year to October 2019 of £1.35 billion (2018 £1.82 billion), resulting in a gross profit of £101.1 million (2018: £94.9 million), and net profit of almost £13.5 million up from £10.1 million in 2018.
Healthcare at home is a subsidiary of Halcyon Topco. Over 75% of Halcyon’s shares, however, are owned by Vitruvian Partners Llp, a European private equity firm.
Healthcare at Home is on the NHS Framework agreements for Pharmacy Dispensing and Delivery Services and for Home Delivery of Intravenous and Subcutaneous Immunoglobulin. The company is the leading deliverer of pharmaceutical products to NHS patients at home.
Pharmacy Homecare Services
In June 2017, the Royal Devon and Exeter NHS Foundation Trust commissioned two contracts for pharmacy homecare services: one for "high tech", worth £22,000,000; and one for "mid and low tech", worth £200,500,000. Out of the total £222,500,000, Healthcare at Home received £211,400,000.
In 2014 Healthcare at Home was bombarded with complaints over its home delivery of essential prescriptions to NHS patients. The largest issue was its failure to deliver all medications - some life-saving - on time. Problems emerged after Healthcare at Home switched from using an in-house delivery service to Movianto: an American logistics firm operating throughout Europe. When Movianto’s IT systems failed many patients were left without deliveries. The company was investigated by the regulator.
Delivery issues appeared again in 2017, with patients not receiving vital medicines and phone calls not being returned.